$TFX News

Teleflex: Strong Company Undergoing Messy Transition, Hold

Teleflex: Portfolio Surgery Creates A Better Medtech Compounder

UBS Maintains Neutral on Teleflex, Raises Price Target to $158

Truist Securities Maintains Hold on Teleflex, Raises Price Target to $150

Piper Sandler Reiterates Overweight on Teleflex, Raises Price Target to $169

Teleflex Incorporated (TFX) Q2 2026 Earnings Call Transcript

Teleflex Incorporated 2026 Q2 - Results - Earnings Call Presentation

Teleflex Lowers FY2026 GAAP EPS Guidance from $2.90-$3.20 to $2.54-$2.84 vs $2.96 Est

Teleflex Raises FY2026 Adj EPS Guidance from $6.25-$6.55 to $6.90-$7.20 vs $6.68 Est; Lowers FY2026 Sales Guidance from $2.280B-$2.300B to $2.260B-$2.280B vs $2.287B Est

Teleflex Q2 Adj. EPS $1.76 Beats $1.28 Estimate, Sales $570.332M Beat $559.596M Estimate

Needham Maintains Buy on Teleflex, Raises Price Target to $159

U.S. FDA Licenses First Freeze-dried Plasma Product Ezplaz In The United States; Ezplaz Available In Group Ab And Group A Low-Titer Anti-B For Emergency Transfusion

UBS Initiates Coverage of Teleflex (TFX) with Neutral Recommendation

UBS Initiates Coverage On Teleflex with Neutral Rating, Announces Price Target of $145

Teleflex Awarded National Premier Contract for Central Venous, Arterial and Intraosseous Access Devices

Mizuho Maintains Neutral on Teleflex, Raises Price Target to $145

BMO Capital Initiates Coverage of Teleflex (TFX) with Outperform Recommendation

BMO Capital Initiates Coverage On Teleflex with Outperform Rating, Announces Price Target of $159

Teleflex Starts Enrollment For Its BIOMAG‑IIII Study Evaluating The Freesolve Resorbable Magnesium Scaffold

Teleflex Presents 4‑Yr Follow‑Up Data From First-in-Human BIOMAG-I Clinical Study At EuroPCR Conference